Piramal Pharma Limited has submitted a regulatory disclosure to the BSE Limited and the National Stock Exchange of India Limited regarding an Environment, Social and Governance (ESG) rating.
The company received information on September 03, 2026, that NSE Sustainability Ratings and Analytics Limited ('NSE Sustainability') has assigned it an ESG Rating of '65' for the financial year 2025-26. This rating is based on data made available by the company in the public domain for that period.
The assigned rating of 65 marks an improvement over the previous score of 64, which the disclosure states reflects the company's "ongoing commitment to sustainability and responsible operations."
The rating is published on the website of NSE Sustainability at https://www.nse-esgrating.com/.
The company explicitly clarifies that it has not engaged NSE Sustainability for this ESG Rating. The report was prepared voluntarily by NSE Sustainability by considering the ESG factors reported by the company.
This intimation is being made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. A copy of the disclosure is also being uploaded on the company's website at https://www.piramalpharma.com/.
The disclosure is signed by Maneesh Sharma, Company Secretary & Compliance Officer of Piramal Pharma Limited.